NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Tuesday that its board of directors has approved a two-for-one split of the firm's common stock, which will take effect next month.

The Salt Lake City-based molecular diagnostics firm said that the split would be effected in the form of a dividend, which is payable on March 25 to shareholders of record at the close of business on March 9. Under the split, shareholders will receive one additional share for each share held.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.